In support of its mission to advance the knowledge and practice of allergy, asthma and immunology for optimal patient care the AAAAI continually endeavors to create effective and visible platforms for advocacy on issues involving the specialty and its patients.
To accomplish this goal, the AAAAI works with professional representatives on Capitol Hill under the leadership of the Practice & Policy and Research & Training Divisions of the Board of Directors. AAAAI Board members regularly visit Washington, DC, to meet with Senators and Representatives as well as agency officials who play leadership roles with respect to health policy and research.
The AAAAI has focused for a number of years on increased funding for research initiatives to promote best practices in the management of allergies, asthma and immune deficiency disorders. To allow the specialty to have an even stronger voice in Washington, the AAAAI recently expanded its advocacy efforts to also include legislative and coding and billing issues.
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to be held on May 17, 2017, from 8:30 a.m. to 4:45 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD 20993-0002. This will be an open session to discuss Respiratory Syncytial Virus vaccine candidates in seronegative infants. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public. The full notice can be found here.